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tional data for patients undergoing lobectomy or wedge resection using open tho-
racotomy. Ourmeasure of volume represents the aggregate experience level of the
surgeon per six month window. Multivariable logistic regression analyses were
estimated for the binary outcome - adverse events. Ordinary Least Squares (OLS)
regression was used for continuous outcomes: hospital costs, surgery time, length
of stay, and number of adverse events. In addition, the following explanatory vari-
ables were included: patient demographics, diagnosis, comorbid conditions, pa-
tient severity index and hospital characteristics. RESULTS: Of 7137 patients in the
database with elective, inpatient resections for lung cancer, a total of 2698 patients
underwent lobectomy (n716) or wedge resection (n1982) using VATS. More than
70% of these procedures were performed by thoracic surgeons (n1896). A positive
volume-outcome relationship appeared as follows: The relationship is stronger for
cost and utilization outcomes versus adverse events, for thoracic surgeons versus
other surgeons, and for VATS lobectomy procedures versus VATS wedge resection
procedures. Finally, we find that while there was a reduction in cost and resource
utilization associatedwith greater experiencewith VATS, these outcomeswere not
strongly linked with greater experience with open procedures. CONCLUSIONS:
There is a reduction in cost and resource utilization associated with greater expe-
riencewithVATS. Greater experiencewith openprocedures does not correlatewith
better VATS outcomes.
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OBJECTIVES: To assess the long-term safety of Laser in situ keratomilieusis (LASIK)
and surface ablation surgery formyopia in South Korea.METHODS:A retrospective
cohort for patients who had a LASIK or surface ablation surgery in 6 hospitals
during 2002-2005 were constructed based on chart reviews and linked to Health
Insurance Review and Assessment (HIRA) claims database during 2005-2009. A
total of 2,422 patients (4,688 eyes) were linked using anonymized identifier after
excluding patients with a history of eye disease, diabetes, hyperopia, or different
surgery methods for both eyes. The frequency of eye disease such as cataract,
glaucoma, retinal detachment, corneal opacity, and keratoconus during 3-8 years
after surgery and the pre-surgery characteristics including age, UCVA (uncorrected
visual acuity), manifest refractive (MR) of patients with eye disease were analyzed.
RESULTS: There were 1,637 LASIK patients and 785 surface ablation patients. The
eye disease after LASIK were cataract (0.2%) and corneal opacity (0.9%) during 3-4
years and cataract (0.1%), glaucoma (0.2%), retinal detachment (0.4%) and corneal
opacity (0.7%) during 4-5 years. The retinal detachment (0.3%) and corneal opacity
(1.3%) were observed during 7-8 years while no keratoconus was identified during
3-8 year follow-up. The pre-surgery MR (meanSD) were 6.981.41 Diopter (D),
7.462.87 D, 6.132.67 D, 6.232.62 D in patients with cataract, glaucoma,
retinal detachment, and corneal opacity, respectively. The incidence of eye disease
after surface ablation was similar to LASIK. CONCLUSIONS: The linkage of clinical
baseline database and nationwide claims database can make up for loss to fol-
low-up in retrospective cohort study. Although it is difficult to explain the causality
of surgery, we could ascertain there was no serious eye disease after surgery.
Surgery – Cost Studies
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OBJECTIVES: To assess the relationship of patient, payer, and hospital character-
istics with cost and mortality in pediatric heart transplant recipients. METHODS:
Data from the 1997, 2000, 2003, and 2006 Agency for Healthcare Research and
Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP) Kids’ Inpatient Da-
tabase (KID) were utilized. Pediatric patients aged 0-17 years receiving heart trans-
plants were included. Logistic regression and generalized linear models were used
for the analyses. Inpatient mortality and inflation-adjusted costs were the out-
comes of interest. Patient demographics and clinical characteristics were the pri-
mary independent variables of interest, with payer and hospital characteristics
used as control variables. Weighting procedures were utilized to yield nationally
representative results. RESULTS: Overall, 1154 patients received heart transplants
during the study timeframe. The average was 6.5 (6.1) years. Mean inpatient
hospital costs were $206,895 (150,504). Inpatient mortality was 7.2%. Children1
year were significantly less likely to die during hospitalization than those 1 year
(p0.05). Hemorrhage (OR4.11, p0.005) and renal failure (OR6.45, p0.001)
were complications associated with mortality. Mortality was also significantly as-
sociated with higher number diagnoses and higher income and inversely related
withWest region andmore recent transplants. Mortality cases incurred 1.68 times
higher costs than those routinely discharged (p0.001). Sepsis (exp(b)1.18,
p0.04), respiratory disease (exp(b)1.08, p0.021), hemorrhage (exp(b)1.22,
p0.001) and renal failure (exp(b)1.15, p0.003) were complications associated
with higher costs. Higher costs were also significantly associated with medium hos-
pital bedsize, age1year, admission fromanother facility, longer lengthsof stay,West
region,more recent transplants andhigher patient income,with lower costs for trans-
plants occurring in a children’s unit of a general hospital. CONCLUSIONS: Multiple
patient and hospital characteristics appear to significantly predict inpatient mor-
tality and costs in pediatric heart transplant recipients.
PSU7
A DISCRETE EVENT SIMULATION MODEL TO ESTIMATE THE LONG TERM
OUTCOMES OF BARIATRIC SURGERY IN MEXICO
Zanela OO1, Cabra HA1, Anaya P2, Rodriguez S1, Melendez G2
1Johnson & Johnson Medical, Mexico City, D.F., Mexico, 2Fundación Mexicana para la Salud AC,
Mexico City, Mexico
OBJECTIVES: Estimate the return of investment (ROI) on bariatric surgery vs. con-
ventional, non-surgical approach as treatment for morbid obesity from the Mexi-
can public health system perspective in the long term. METHODS: The individual
experience of a morbidly-obese patient was assessed using a discrete event simu-
lation model built in Arena™. Patients were created with unique, randomly as-
signed clinical and epidemiologic characteristics, cloned and sent to either bariat-
ric surgery (BS) or conventional treatment – pharmacologic treatment of associated
comorbidities and lifestyle modifications (control arm). Evaluated comorbidities
were type-2 diabetes, hypertension and hypercholesterolemia. Preoperative prev-
alences and up-to year 2 recovery rates were taken from publishedmeta-analyses.
2- and 10-year prevalences were derived from incidence and recovery rates shown
in SOS study; in-between prevalences were interpolated assuming exponential
growth, thus allowing clinical state worsening in both arms. Additional assump-
tions include infrastructure restrictions, no perioperative complications and short
term mortality. 5% of patients in control group were allowed to have surgery after
year 5. Considered costs included the bariatric procedure and comorbidity-specific
pharmacologic treatment, taken from public health institution’s DRGs. Simulation
was run with 150 patients for 10 years and 10 iterations using a 4.5% annual dis-
count rate. Results are shown in years and 2010 inflation-adjusted MXP. 95% con-
fidence intervals were estimated. RESULTS: 10-year accumulated cost for a BS
patient was $125,902 ($125,041-$ 126,763), and $259,413 ($258,098 - $260,728) for a
control patient. ROI on BSwas achieved on year 6.94 (6.88-7.00). Cost differences are
due to the reduced resource utilization after surgery resulting from resolution of
comorbidities. CONCLUSIONS: Investment in BS offsets its cost and is recouped
within a reasonable time, thus allowing institutions to reduce the burden imposed
by morbid obesity. Long-run data for other associated comorbidities is needed, as
their inclusion in the analysis could decrease ROI.
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OBJECTIVES:Treatment guidelines stipulate that clopidogrel should be interrupted
5 days prior to elective coronary artery bypass grafting (CABG) to reduce the risk
of bleeding. However, if urgent CABG is indicated, experienced surgeons may per-
form CABG in 5 days. This study is the first to describe patterns of acute clopi-
dogrel use and inpatient costs among acute coronary syndrome (ACS) patients
undergoing CABG, which will help decision makers understand the relative bene-
fits/costs of antiplatelet therapies in real-world practices. METHODS: The study
used the MarketScan® Commercial, Medicare, and Hospital Drug Databases, com-
prising administrative healthcare data for over 63 million individuals. ACS epi-
sodes, defined as hospitalizations for ACS (primary ICD-9-CM diagnosis 410.xx,
411.1x), occurring between 1/1/2005-6/30/2009 were identified from patients aged
18 years. Outcomes included costs and lengths of stay (LOS) of ACS episodes with
CABG and, among clopidogrel-treated patients, number of days between the day
CABG was performed and the last clopidogrel dose administered. Analyses were
descriptive. RESULTS: 160,168 ACS episodes were identified; mean patient age 
63.5 years. CABG episodes comprised 9.3% (14,896/160,168) of ACS episodes. The
mean LOS was 9.8 [SD 6.8] days per CABG episode. Mean inpatient costs were
$71,140 [SD $68,012] per CABG episode. Among clopidogrel-treated patients with
inpatient drug data who underwent CABG (n8,101), the mean days between the
day CABGwas performed and the last dose of clopidogrel administered was 3.3 [SD
2.6] days and themajority (62.1%) underwent surgerywithin 2-3 days after their last
clopidogrel dose. Themean incremental increase in inpatient costs associatedwith
1 extra LOS day was $1,950. CONCLUSIONS:Data suggest that surgeons commonly
perform CABG within 5 days after clopidogrel administration. However, among
patients for whom urgent CABG is not indicated, withholding CABG may only
minimally affect inpatient costs and must be considered in the broader context of
patient management.
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OBJECTIVES: The purpose of the study was to quantify the potential effect of the
current trend towardsmore uncemented primary total hip arthroplasties (THAs) in
terms of hospital costs and number of revisions over a 10 year period (2011 to 2021)
in England andWales. In addition the potential impact of changes of this develop-
ment was evaluated.METHODS: Registry data from the National Joint Registry for
England andWales from 2004 to 2009was used to predict the numbers of THAs and
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